# Bob Ragusa

Type: Person

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/bob-ragusa
Canonical HTML page: https://getfinancebrief.com/entity/bob-ragusa

## Timeline

- **2026-03-22**: Market Outperformance — Financial media highlights Grail as the week's top performer in the diagnostics sector.
- **2026-03-20**: Volume Surge — Stock sees highest trading volume in six months as institutional buyers return.
- **2026-03-18**: TD Cowen Upgrade — Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
- **2026-03-16**: Market Low — GRAL stock hits a 52-week low amid heavy selling pressure.
- **2026-03-13**: CEO Transition — Bob Ragusa steps down as CEO following reports of a trial setback.

## Recent coverage (1 stories)

### Grail Shares Surge as Market Reassesses NHS Trial Setback and TD Cowen Upgrade
2026-03-22 12:13:11 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
Full story: https://getfinancebrief.com/story/grail-gral-stock-rally-march-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.